Infliximab biosimilar - Biocad
Alternative Names: BCD-055Latest Information Update: 29 Dec 2021
At a glance
- Originator Biocad
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Ankylosing spondylitis; Rheumatoid arthritis
Most Recent Events
- 24 Apr 2019 Biocad completes a phase III trial in Rheumatoid arthritis in India and Russia (IV) (CTRI2017-03-008063)
- 13 Jun 2018 Efficacy and adverse events data from the phase III ASART-2 trial in Ankylosing spondylitis presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
- 13 Jun 2018 Efficacy, adverse events and immunogenicity data from the phase III LIRA trial in Rheumatoid arthritis presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)